Home
/
Data resources
/
Literature
/
238716
Effect of new beta-adrenergic blocking agent, Atenolol (Tenormin), on pain frequency, trinitrin consumption, and exercise ability.

Br Med J, 1975/7/26;3(5977):195-7.

Roy P, Day L, Sowton E

PMID: 238716

Abstract
In 11 patients with severe angina pectoris a new beta-blocking drug, atenolol (Tenormin; I.C.I.66082), was found in a double-blind randomized trial to reduce significantly the frequency of anginal attacks (P less than 0-001) and the amount of trinitrin consumed (P less than 0-03) in comparison with practolol and placebo. There was no significant improvement in the patients' ability to exercise on the bicycle ergometer.
MeSH terms
Administration, Oral; Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Humans; Male; Middle Aged; Nitroglycerin; Pain; Physical Exertion; Placebos; Practolol; Pulse
More resources
EndNote: Download